ProCE Banner Activity

VISION: HRQoL, Pain, and Safety Outcomes With 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Slideset Download
Conference Coverage

In patients with previously treated mCRPC, the addition of 177Lu-PSMA-617 to standard of care resulted in improvements in health-related quality of life and time to worsening of pain and first symptomatic skeletal events, in addition to the previously reported OS and rPFS benefits.

Released: September 30, 2021

Expiration: September 29, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc